Giant Cell Arteritis
📧 Sign up to get email alerts when something new happens for Giant Cell Arteritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-07-22Clinical Trial Update: PET Imaging of Giant Cell and Takayasu Arteritis
Clinical trial update describing PET imaging studies in giant cell arteritis and Takayasu arteritis, sponsored by the University of Cambridg…
-
CLINICAL_TRIALS research · 2024-07-15Clinical Trial Update: Visual Involvement in Giant Cell Arteritis
A clinical trial update indicates a study on visual involvement in giant cell arteritis is currently recruiting, focusing on ocular complica…
-
CLINICAL_TRIALS research · 2024-06-04Clinical Trial Update: Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim)
The EvHortim study is a clinical trial evaluating post-therapeutic imaging in patients with giant cell arteritis and is currently recruiting…
-
CLINICAL_TRIALS research · 2024-05-09Clinical Trial Update: Investigation of the Influence of the Human Microbiome on Giant Cell Arteritis
A clinical trial investigating how the human microbiome might influence Giant cell arteritis, sponsored by the University of Bonn, currently…
-
CLINICAL_TRIALS trial_result · 2024-04-10Clinical Trial Update: Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis [Phase 2]
Phase 2 clinical trial evaluating methotrexate as remission maintenance therapy after remission-induction with tocilizumab and glucocorticoi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-03-05FDA Approved: TYENNE — Original Application (Fresenius Kabi USA, LLC)
FDA approved TYENNE (tocilizumab-AAZG) from Fresenius Kabi USA, LLC under an Original Application.
-
CLINICAL_TRIALS trial_result · 2023-10-18Clinical Trial Update: Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA) [Phase 2]
Phase 2 trial update on Gallium-68 HA-DOTATATE PET/CT imaging for Giant Cell Arteritis has completed.
-
CLINICAL_TRIALS trial_result · 2023-10-17Clinical Trial Update: KPL-301 for Subjects With Giant Cell Arteritis [Phase 2]
Phase 2 clinical trial update for KPL-301 in giant cell arteritis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-04-26Clinical Trial Update: A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis [Phase 2]
Phase 2 trial evaluating safety and efficacy of secukinumab in Giant Cell Arteritis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-12-02Clinical Trial Update: Tocilizumab Plus a Short Prednisone Taper for GCA [Phase 4]
A Phase 4 trial evaluating tocilizumab with a short prednisone taper for giant cell arteritis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-04-08Clinical Trial Update: Baricitinib in Relapsing Giant Cell Arteritis [Phase 2]
Phase 2 trial update for baricitinib in relapsing giant cell arteritis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-03-18Clinical Trial Update: Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA [Phase 2]
Phase 2 clinical trial evaluating tocilizumab for acute anterior ischemic optic neuropathy related to giant cell arteritis.
-
CLINICAL_TRIALS trial_result · 2022-01-14Clinical Trial Update: Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of sarilumab in giant cell arteritis was terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2021-12-22Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA). [Phase 1]
Phase 1 trial update evaluating pharmacokinetics, pharmacodynamics, and safety of Tocilizumab in Giant Cell Arteritis has completed with res…
-
FDA approval · 2021-10-22FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Actemra (tocilizumab) from Genentech, expanding its labeling and/or indications. The action conf…
-
CLINICAL_TRIALS trial_result · 2021-06-22Clinical Trial Update: Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab [Phase 1, Phase 2]
Phase 1/2 trial investigating ultra-short glucocorticoids with tocilizumab for giant cell arteritis has completed.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering [Phase 3]
Phase 3 trial update comparing two standardized corticosteroid tapering regimens for giant cell arteritis; recruitment not yet started.
-
CLINICAL_TRIALS trial_result · 2020-09-04Clinical Trial Update: An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) [Phase 3]
An extension study to evaluate the long-term safety of subcutaneous tocilizumab in participants with giant cell arteritis completed.
-
CLINICAL_TRIALS trial_result · 2020-06-12Clinical Trial Update: Ustekinumab for the Treatment of Giant Cell Arteritis [Phase 1, Phase 2]
Phase 1/2 trial of ustekinumab for Giant Cell Arteritis was terminated, with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-05-28Clinical Trial Update: Assessment of Giant Cell Arteritis Medical Practices in France
A completed clinical trial assessing medical practices for Giant Cell Arteritis in France; results posted in 2020.
-
FDA approval · 2019-06-11FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Actemra (tocilizumab) filed by Genentech, Inc., resulting in an approved update to the product's…
-
CLINICAL_TRIALS trial_result · 2019-05-31Clinical Trial Update: Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis [Phase 3]
Phase 3 trial of sirukumab in giant cell arteritis was terminated; results posted in 2019.
-
CLINICAL_TRIALS research · 2019-02-15Clinical Trial Update: Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO [Phase 3]
Phase 3 clinical trial evaluating early treatment with bosentan for sudden blindness due to giant cell arteritis; status is currently unknow…
-
CLINICAL_TRIALS trial_result · 2019-02-12Clinical Trial Update: Tocilizumab for Patients With Giant Cell Arteritis [Phase 2]
Phase 2 trial evaluating tocilizumab for giant cell arteritis has completed and posted results.
-
CLINICAL_TRIALS research · 2018-06-06Clinical Trial Update: Journey of Patients With Vasculitis From First Symptom to Diagnosis
A completed University of Pennsylvania clinical study tracks vasculitis patients from first symptoms through diagnosis, describing the diagn…